Moreover, non‐invasive CD38 monitoring is expected to have a broader application across different disease states of MM and may be applicable to a range of malignancies with known CD38 involvement, such as NK/T cell lymphoma, T‐cell acute lymphoblastic leukemia, and primary effusion lymphoma. The gene discussed is CD38; the disease is Miyoshi myopathy.